The role of Hedgehog pathway in colorectal cancer

doi:10.3760/cma.j.issn.1673,422X.2016.01.018

Abstract

Abstract: Hedgehog (Hh) signaling pathway is closely associated with the development of various types of human tumors. Recent studies have reported that Hh pathway plays an important role in oncogenesis, metastasis and therapy of colorectal neoplasms. Currently, Hh signals have been detected highly expressed in colorectal cancer tissues and cells. Inhibition of this pathway can deeply restrain the invasion and metastasis of colorectal cancer cells. And it has become a hot topic that Hh pathway is used as a target in the treatment of colorectal cancer.

Key words: Colorectal neoplasms, Neoplasm metastasis, Therapy, Hedgehog signaling pathway

Bi Yanzhen, Kong Lingbin. The role of Hedgehog pathway in colorectal cancer[J]. Journal of International Oncology, 2016, 43(1): 64-66.

References

［1］ Wang Q, Huang Z, Ni S, et al. Plasma miR601 and miR760 are novel biomarkers for the early detection of colorectal cancer［J］. PLoS One, 2012, 7(9): e44398. DOI:10.1371/journal.pone.0044398. ［2］ Lu JT, Zhao WD, He W, et al. Hedgehog signaling pathway mediates invasion and metastasis of hepatocellular carcinoma via ERK pathway［J］. Acta Pharmacol Sin, 2012, 33(5): 691-700. DOI:10.1038/aps.2012.24. ［3］ Oue T, Uehara S, Yamanaka H, et al. Hedgehog signal inhibitors suppress the invasion of human rhabdomyosarcoma cells［J］. Pediatr Surg Int, 2013, 29(11): 1153-1158. DOI:10.1007/s00383-013-3369-6. ［4］ Wang H, Li YY, Wu YY, et al. Expression and clinical significance of hedgehog signaling pathway related components in colorectal cancer［J］. Asian Pac J Cancer Prev, 2012, 13(5): 2319-2324. ［5］ Wang HT, Ke F, Zheng J. Hedgehoggliomaassociated oncogene homolog1 signaling in colon cancer cells and its role in the celecoxibmediated anticancer effect［J］. Oncol Lett, 2014, 8(5): 22032208. DOI:10.3892/ol.2014.2439. ［6］ Wu JY, Xu XF, Xu L, et al. Cyclopamine blocked the growth of colorectal cancer SW116 cells by modulating some target genes of Gli1 in vitro［J］. Hepatogastroenterology, 2011, 58(110/111): 15111518. DOI:10.5754/hge10765. ［7］ Batsaikhan BE, Yoshikawa K, Kurita N, et al. Cyclopamine decreased the expression of Sonic Hedgehog and its downstream genes in colon cancer stem cells［J］. Anticancer Res, 2014, 34(11): 6339-6344. ［8］ Wang ZC, Gao J, Zi SM, et al. Aberrant expression of sonic hedgehog pathway in colorectal cancer and melanosis coli［J］. J Dig Dis, 2013, 14(8): 417423. DOI:10.1111/1751-2980.12060. ［9］翁子毅, 子树明, 杨明，等. Hedgehog 信号通路活化在结直肠病变的意义［J］. 上海医学, 2011, 34(5): 379-381. ［10］ Stefanius K, Kantola T, Tuomisto A, et al. Downregulation of the hedgehog receptor PTCH1 in colorectal serrated adenocarcinomas is not caused by PTCH1 mutations［J］. Virchows Arch, 2011, 458(2): 213219. DOI:10.1007/s00428-010-1031-4. ［11］ Iwasaki H, Nakano K, Shinkai K, et al. Hedgehog Gli3 activator signal augments tumorigenicity of colorectal cancer via upregulation of adherencerelated genes［J］. Cancer Sci, 2013, 104(3): 328336. DOI:10.1111/cas.12073. ［12］ Fu X, Shi L, Zhang W, et al. Expression of Indian hedgehog is negatively correlated with APC gene mutation in colorectal tumors［J］. Int J Clin Exp Med, 2014, 7(8): 2150-2155. ［13］谭玉旻, 魏正强, 崔发强. Hedgehog 信号通路效应蛋白在大肠癌组织中的表达及意义［J］. 重庆医学, 2010, 39(19): 25732575. DOI:10.3969/j.issn.16718348.2010.19.011. ［14］ Ruiz i Altaba A. Hedgehog signaling and the Gli code in stem cells, cancer, and metastases［J］. Sci Signal, 2011, 4(200): pt9. DOI:10.1126/scisignal.2002540. ［15］ Ding YL, Wang QS, Zhao WM, et al. Expression of smoothened protein in colon cancer and its prognostic value for postoperative liver metastasis［J］. Asian Pac J Cancer Prev, 2012, 13(8): 4001-4005. ［16］ Song J, Zhang J, Wang J, et al. β1 integrin mediates colorectal cancer cell proliferation and migration through regulation of the hedgehog pathway［J］. Tumour Biol, 2015, 36(3): 2013-2021. DOI:10.1007/s13277-014-2808-x. ［17］ Wang TP, Hsu SH, Feng HC, et al. Folate deprivation enhances invasiveness of human colon cancer cells mediated by activation of sonic hedgehog signaling through promoter hypomethylation and cross action with transcription nuclear factorkappa B pathway［J］. Carcinogenesis, 2012, 33(6): 1158-1168. DOI:10.1093/carcin/bgs138. ［18］ Varnat F, SieglCachedenier I, Malerba M, et al. Loss of WNTTCF addiction and enhancement of HHGLI1 signalling define the metastatic transition of human colon carcinomas［J］. EMBO Mol Med, 2010, 2(11): 440-457. DOI:10.1002/emmm.201000098. ［19］ Lee MJ, Hatton BA, Villavicencio EH, et al. Hedgehog pathway inhibitor saridegib (IPI926) increases lifespan in a mouse medulloblastoma model［J］. Proc Natl Acad Sci USA, 2012, 109(20): 7859-7864. DOI:10.1073/pnas.1114718109. ［20］ Jimeno A, Weiss GJ, Miller WH Jr, et al. Phase Ⅰ study of the Hedgehog pathway inhibitor IPI926 in adult patients with solid tumors［J］. Clin Cancer Res, 2013, 19(10): 2766-2773. DOI:10.1158/1078-0432.CCR-12-3654. ［21］ Mazumdar T, Devecchio J, Agyeman A, et al. Blocking hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells［J］. Cancer Res, 2011, 71(17): 5904-5914. DOI:10.1158/00085472.CAN-10-4173. ［22］ Kang HN, Oh SC, Kim JS, et al. Abrogation of Gli3 expression suppresses the growth of colon cancer cells via activation of p53［J］. Exp Cell Res, 2012, 318(5): 539-549. DOI:10.1016/j.yexcr.2011.12.010. ［23］ Agyeman A, Jha BK, Mazumdar T, et al. Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLIDNA binding［J］. Oncotarget, 2014, 5(12): 4492-4503. ［24］黄璇, 张伟龙, 罗清甜，等. 抑制Hedgehog信号通路改变结肠癌细胞基因表达谱［J］. 中国细胞生物学学报, 2012, 34(9): 886898. ［25］ ElZaatari M, Daignault S, Tessier A, et al. Plasma Shh levels reduced in pancreatic cancer patients［J］. Pancreas, 2012, 41(7): 10191028. DOI:10.1097/MPA.0b013e31824a0eeb.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[7]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[8]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[9]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[10]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[11]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[12]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[13]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[14]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[15]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.